Global Epidemiology of Tuberculosis

Philippe Glaziou, Charalambos Sismanidis, Katherine Floyd, and Mario Raviglione

HIV/AIDS, Tuberculosis & Malaria, World Health Organization, 1211 Geneva 27, Switzerland
Correspondence: glazioup@who.int

Despite the availability of effective chemotherapy, tuberculosis (TB) killed 1.3 million people in 2012. Alongside HIV, it remains a top cause of death from an infectious disease. Global targets for reductions in the epidemiological burden of TB have been set for 2015 and 2050 within the context of the Millennium Development Goals (MDGs) and by the Stop TB Partnership. Achieving these targets is the focus of national and international efforts in TB control, and showing whether or not they are achieved is of major importance to guide future and sustainable investments. This article provides a short overview of sources of data to estimate TB disease burden; presents estimates of TB incidence, prevalence, and mortality in 2012 and an assessment of progress toward the 2015 targets for reductions in these indicators based on trends since 1990 and projections up to 2015; analyzes trends in TB notifications and in the implementation of the Stop TB Strategy; and considers prospects for elimination of TB after 2015.

Tuberculosis (TB) is likely to have affected humans for most of their history (Holloway et al. 2011; Comas et al. 2013) and remains a major cause of death worldwide despite the discovery of effective and affordable chemotherapy more than 50 years ago. With 1.3 million TB deaths (including TB deaths in HIV-positive individuals) in 2012 (WHO 2013a), TB and the human immunodeficiency virus (HIV) are the top causes of death from a single infectious agent worldwide (Lozano et al. 2012; Ortblad et al. 2013). TB is a leading killer among adults in the most economically productive age groups and people living with HIV (Lopez et al. 2006), and even those cured from TB can be left with lifetime sequelae that substantially reduce their quality of life (Miller et al. 2009). Recognition of these facts has kept TB control high on the international public health agenda since the early 1990s (Zumla et al. 2009; Lienhardt et al. 2012a), following years of neglect during the 1980s (Raviglione and Pio 2002).

Evidence that chemotherapy is among the most cost-effective of all health-care interventions (Murray et al. 1991; Dye and Floyd 2006), the catastrophic impact of the HIV epidemic on TB in Africa, and the global concern about the growth of multidrug-resistant TB (MDR-TB) have emphasized the need to improve TB prevention and control. Global targets for reductions in the epidemiological burden of TB have been set for 2015 and 2050 within the context of the Millennium Development Goals (MDGs) and separately by the Stop TB Partnership, a global coalition of stakeholders established to coordinate international efforts...
The WHO’s recommended approach for achieving these targets is the Stop TB Strategy (Raviglione and Uplekar 2006), which comprises best practices in the diagnosis and treatment of patients with active TB, approaches to address major epidemiological and system challenges, and the promotion of research for innovations (Box 2). It was launched in 2006 and underpins the Global Plan 2011–2015, a comprehensive and budgeted plan to reach the global targets (Raviglione 2006b; 2007; Korenromp et al. 2012).

Reaching the 2015 targets has been the focus of national and international efforts in TB control for more than a decade, and the World Health Organization (WHO) has established a Global Task Force on TB Impact Measurement (Dye et al. 2008) to ensure the best possible evaluation of whether or not they are achieved. Every year, WHO publishes estimates of TB incidence, prevalence, and mortality at global, regional, and country levels, along with an analysis of progress toward achievement of global targets (WHO 2013a).

This article provides an overview of sources of data to estimate the burden of disease; presents estimates of the global burden of TB in 2012 and trends in incidence, prevalence, and mortality from 1990 to 2012, with projections up to 2015; analyzes trends in TB notifications and in the implementation of the Stop TB Strategy; and considers prospects for elimination of TB after 2015. Special attention is given to drug-resistant TB, the association of TB with HIV, and TB in children.

**GLOBAL MONITORING OF THE BURDEN OF TB**

TB incidence has never been measured at the national level because this would require long-term studies among large cohorts of people (hundreds of thousands) at high cost and with challenging logistics. The best approach to estimating TB incidence is from routine surveillance systems in which case reports are more or less complete, such that notifications can be considered a close proxy of incidence. This is possible in settings with universal healthcare coverage (Moreno-Serra and Smith 2012; O’Neill et al. 2013), and in which operational research has been used to quantify the small fraction of cases that are treated but not notified to surveillance systems (Van Hest et al. 2008). However, surveillance systems in many countries are not yet capable of providing a direct measure of TB incidence because the numbers of cases who are treated but not notified, or undiagnosed at all, are unknown. The major reasons why cases are missed from official notifica-
**BOX 2. STOP TB STRATEGY** (Raviglione and Uplekar 2006; World Health Organization 2007)

**Vision, Goal, Objectives, and Targets**

**Vision:** A world free of TB

**Goal:** To dramatically reduce the global burden of TB by 2015 in line with the Millennium Development Goals and the Stop TB Partnership targets

**Objectives:**
- Achieve universal access to high-quality diagnosis and patient-centered treatment
- Reduce the human suffering and socioeconomic burden associated with TB
- Protect poor and vulnerable populations from TB, TB/HIV, and multidrug-resistant TB
- Support development of new tools and enable their timely and effective use

**Targets:**
- MDG 6, Target 8: . . . halted by 2015 and begun to reverse the incidence . . .
- Targets linked to the MDGs and endorsed by the Stop TB Partnership:
  - by 2005: detect at least 70% of new sputum smear-positive TB cases and cure at least 85% of these cases
  - by 2015: reduce prevalence of and death due to TB by 50% relative to 1990
  - by 2050: eliminate TB as a public health problem (less than one case per million population)

**Components of the Stop TB Strategy**

1. **Pursue high-quality DOTS expansion and enhancement**
   - Secure political commitment, with adequate and sustained financing
   - Ensure early case detection, and diagnosis through quality-assured bacteriology
   - Provide standardized treatment with supervision, and patient support
   - Ensure effective drug supply and management
   - Monitor and evaluate performance and impact

2. **Address TB-HIV, MDR-TB, and the needs of poor and vulnerable populations**
   - Scale-up collaborative TB/HIV activities
   - Scale-up prevention and management of multidrug-resistant TB (MDR-TB)
   - Address the needs of TB contacts, and of poor and vulnerable populations

3. **Contribute to health system strengthening based on primary health care**
   - Help improve health policies, human resource development, financing, supplies, service delivery, and information
   - Strengthen infection control in health services, other congregate settings, and households
   - Upgrade laboratory networks, and implement the Practical Approach to Lung Health (PAL)
   - Adapt successful approaches from other fields and sectors, and foster action on the social determinants of health

4. **Engage all care providers**
   - Involve all public, voluntary, corporate, and private providers through Public-Private Mix (PPM) approaches
   - Promote use of the International Standards for Tuberculosis Care (ISTC)

*Continued*
tion data include laboratory errors (Botha et al. 2008), lack of notification of cases by public (Dye et al. 1999) and private providers (Uplekar et al. 2001), failure of health-care staff to recognize TB signs and symptoms among people accessing health services (Meintjes et al. 2008), and lack of access to health services (Veron et al. 2004). Operational research (such as capture-recapture studies) as well as supporting evidence (such as whether prescriptions for TB drugs are available in the private sector, and practices of staff managing people suspected of having TB in primary health-care facilities) can be used to assess the plausible range of the fraction of cases that are unaccounted for in case notification data (Borgdorff et al. 2004; Cailhol et al. 2005; Baussano et al. 2006; Crofts et al. 2008; Van Hest et al. 2008; WHO 2013a). Duplicated or misclassified records (Bierrenbach et al. 2007), inconsistent case notification data at the subnational level, inconsistent time trends, or inconsistencies with existing knowledge about TB epidemiology (Dye et al. 2007) all contribute to uncertainty about TB incidence estimates obtained from case notification data.

In contrast to incidence, TB prevalence can be directly measured in nationwide population-based surveys in countries with a high burden of TB (Glaziou et al. 2008; WHO 2011c). Since 2002, 19 countries have successfully measured the prevalence of TB disease through such surveys (Hong et al. 1998; Tupasi et al. 1999; Dye et al. 2000; Soemantri et al. 2007; WHO 2013a) including seven in Africa, and 14 more (eight in Africa) have planned to implement a survey by 2015. Repeat surveys conducted about every 10 years allow trends in disease burden to be assessed. Countries that have completed repeat surveys in the last 10 years include Cambodia, China, the Philippines, and Thailand, and repeat surveys are planned in Myanmar and Vietnam (WHO 2013a). Prevalence surveys have proved extremely useful for designing and adapting national TB control program strategies. A large proportion of the global burden of TB as expressed in terms of TB prevalence will be directly measured from population-based surveys by 2015, as opposed to indirectly estimated from statistical modeling.

TB mortality among HIV-negative people can be directly measured using data from national vital registration (VR) systems, provided that these systems have high coverage and causes of death are accurately coded according to the latest revision of the International classification of diseases (ICD-10) (Korenromp et al. 2009). Sample VR systems covering representative areas of the country (e.g., China) provide an interim solution. Direct measurements of TB mortality from 123 countries were used in 2012 (WHO 2013a). The parts of the world where there are major gaps in the availability of VR data are the African region and parts of the Southeast Asia region; in the latter, Indonesia is currently building a sample VR system.

TB mortality among HIV-positive people is hard to measure even when national VR systems with standard coding of causes of death are in place, because deaths among HIV-positive people are coded as HIV deaths and contributory causes (such as TB) are generally not reliably recorded. This will need to be corrected to permit a comprehensive assessment of TB mortality, especially in countries with a high prevalence of HIV. In the interim, well-monitored cohorts of HIV-positive people who are enrolled in care

**BOX 2. Continued**

5. Empower people with TB, and communities through partnership
   - Pursue advocacy, communication, and social mobilization
   - Foster community participation in TB care
   - Promote use of the Patients’ Charter for Tuberculosis Care

6. Enable and promote research
   - Conduct program-based operational research, and introduce new tools into practice
and/or autopsy studies provide very useful data on contributory causes of AIDS deaths. Starting in 2013, estimates of TB mortality among HIV-positive people are obtained using models implemented in the Spectrum software (see http://www.futuresinstitute.org/spectrum.aspx) (WHO 2013a).

The incidence of and mortality from MDR-TB can be estimated from periodic surveys or from routine drug-susceptibility testing (DST) if the coverage of patient testing is sufficiently comprehensive (WHO 2013a). The global surveillance of resistance to at least the two most important first-line anti-TB drugs—isoniazid and rifampicin—has been coordinated by the WHO since 1994 (Pablos-Mendez et al. 1998; Zignol et al. 2012). Extensively drug-resistant TB (XDR-TB) is defined as MDR-TB plus resistance to the two most effective classes of second-line drugs—the fluoroquinolones and second-line injectable drugs (the aminoglycosides amikacin and kanamycin, and the polypeptide capreomycin) (WHO 2006).

TB EPIDEMIOLOGY

TB is contagious and airborne (Riley 1983). The risk of acquiring *Mycobacterium tuberculosis* infection is essentially determined by exogenous factors. TB is most commonly transmitted from a person with infectious pulmonary TB to others by droplet nuclei, which are aerosolized by coughing, sneezing, or speaking. Other routes of transmission are uncommon and of no epidemiologic significance. The probability of contact with a person who has an infectious form of TB, the intimacy and duration of that contact, the degree of infectiousness of the case, and the shared environment in which the contact takes place are important determinants of the likelihood of transmission. About one-third of the world’s population is estimated to have been exposed to TB bacteria and potentially infected (WHO 2013a). Of those infected, only a small proportion will become sick with TB (Vynnycky and Fine 2000; Borgdorff et al. 2011) but people living with HIV, people with weakened immune systems caused by the prolonged use of medicines such as steroids or TNF-α inhibitors, and patients with diabetes, renal insufficiency, and silicosis (among other morbidities) have a much greater risk of falling ill from TB. Among HIV-uninfected the risk of death after 10 years has been variously reported between 53% and 86%, with a weighted mean of 70% (Tiemersma et al. 2011), compared with ~3% of HIV-uninfected treated tuberculosis patients expected to die because of TB (Straetemans et al. 2011). TB is a disease of poverty that thrives where social and economic determinants of ill health prevail, and that affects mostly young adults in their most productive years living in the developing world (WHO 2013a).

Incidence

In 2012, there were an estimated 8.6 million incident cases of TB (range, 8.3 million–9.0 million) in the world, equivalent to 122 cases per 100,000 population. The absolute number of incident cases has been decreasing, albeit slowly, since the early 2000s (WHO 2013a). Most of the estimated cases in 2012 occurred in the WHO regions of Southeast Asia, the western Pacific (58%), and the African region (27%); smaller proportions of cases occurred in the eastern Mediterranean region (8%), the European region (4%), and the region of the Americas (3%). The largest number of incident cases in 2012 was in India (uncertainty range 2.0 million–2.4 million) corresponding to 26% of global cases, China (0.9 million–1.1 million), and South Africa (0.4 million–0.6 million). Of the 8.6 million incident cases, an estimated 0.5 million were children and 2.9 million (2.7–3.1 million) occurred among women.

The incidence rate varies widely among countries (Fig. 1). The lowest rates are found predominantly in high-income countries including most countries in Western Europe, Canada, the United States of America, Australia, and New Zealand. In these countries, the incidence rate is less than 10 cases per 100,000 population. Most countries in the region of the Americas have rates below 50 per 100,000 population and this is the region with the lowest burden...
of TB on average. Countries in the top 10 worldwide in terms of incidence rates are mostly in Africa. In South Africa and Swaziland, the best estimate is that at least one in every 100 people develops TB each year. Globally, the incidence rate was relatively stable from 1990 up to around 2001, and then started to decrease, achieving the MDG target ahead of the 2015 deadline. Between 2011 and 2012, the rate of decline was 2% (Fig. 2, left panel). This downward trend needs to be sustained to ensure that the MDG target is met in 2015. Incidence rates are also declining in all of six WHO regions, fastest in the European region.

![Figure 1: Estimated tuberculosis incidence rates per 100,000 population, 2012.](image1)

**Figure 1.** Estimated tuberculosis incidence rates per 100,000 population, 2012.

---

**Figure 2.** Global trends in estimated TB incidence and estimated TB mortality. (Left) Global trends in estimated incidence including HIV-negative and HIV-positive TB (dark gray, top) and estimated incidence of HIV-positive TB (light gray, bottom). The dashed line shows global trends in case notification rates (all forms of TB). (Middle) Global trends in estimated TB mortality excluding TB-associated AIDS deaths. The dotted line represents the Stop TB Partnership targets of halving mortality by 2015 compared with the level of 1990. (Right) Global trends in estimated TB prevalence. The dotted line represents the Stop TB Partnership targets of halving prevalence by 2015 compared with the level of 1990. Shaded areas represent uncertainty bands.
(6.5% per year) and slowest in the eastern Mediterranean and Southeast Asia regions (<1% per year and 2% per year, respectively). Incidence rates have been decreasing since the mid-1990s in the eastern Mediterranean region and since around 2000 in the Southeast Asia region; they peaked around 1997 in the European region and around 2002 in the African region, and have been decreasing since 1990 in the region of the Americas and the western Pacific region.

Mortality

There were an estimated 1.3 million TB deaths in 2012: 940,000 among HIV-negative people and 320,000 among HIV-positive people. These deaths included 410,000 among women and 74,000 among HIV-negative children. Approximately 75% of total TB deaths occurred in the African and South-East Asia Regions in 2012 (both including and excluding TB deaths among HIV-positive people). India and South Africa accounted for about one-third of global TB deaths.

The number of TB deaths per 100,000 population averaged 13 globally in 2012 and 17.6 when TB deaths among HIV-positive people are included. There is considerable variation among countries, ranging from less than one TB death per 100,000 population (examples include most countries in western Europe, Canada, the United States of America, Australia and New Zealand) to more than 40 deaths per 100,000 population in much of the African region as well as three high burden countries (HBCs) in Asia (Bangladesh, Cambodia, and Myanmar).

Globally, mortality rates (excluding deaths among HIV-positive people) have decreased by 45% since 1990 (Fig. 2, central panel); the current forecast suggests that the international target of a 50% reduction in TB mortality by 2015 compared with a baseline of 1990 will be achieved. Mortality rates are declining in all six WHO regions (Fig. 3). The 2015 target has already been surpassed in the region of the Americas (since 2004) and the western Pacific region (since 2002), and may have been reached in the eastern Mediterranean region. Among the other three regions, the Southeast Asia region appears best placed to achieve the target. The resurgence of TB mortality in Eastern European countries during the 1990s can be explained by the major political, economic, and social disruption associated with the breakup of the Soviet Union in 1991 and related failures in TB control and provision of health care (Shilova and Dye 2001).

Prevalence

There were an estimated 12 million prevalent cases (11 million–13 million) of TB in 2012, equivalent to 169 cases per 100,000 population. By 2012, the prevalence rate had decreased 37% globally since 1990 (Fig. 2, right panel). Current forecasts suggest that the Stop TB Partnership target of halving TB prevalence by 2015 compared with a baseline of 1990 will not be met worldwide.

Regionally, prevalence rates are declining in all six WHO regions. The region of the Americas halved the 1990 level of TB prevalence by around 2004, well in advance of the target year of 2015, and the best estimate suggests that the Western Pacific Region achieved the 50% reduction target in 2012. Reaching the 50% reduction target by 2015 appears feasible in the Southeast Asia region and also in the European region with a relatively small acceleration in the current rate of progress. The target appears out of reach in the African and eastern Mediterranean regions. In Africa, prevalence rates increased substantially during the 1990s, and by 2007 were still far above the 1990 level. With limited access to antiretroviral therapy (ART), HIV has probably had a smaller effect on TB prevalence than on incidence because the duration of TB among HIV-infected patients is relatively short: for people with advanced HIV infection, the progression to severe tuberculosis is rapid, with a marked reduction in life expectancy (Corbett et al. 2004).

Case Notifications and Treatment Success

Routine recording and reporting of the numbers of TB cases diagnosed and treated by NTPs and monitoring of treatment outcomes was one
of the five components of the global TB strategy (DOTS) launched by WHO in the mid-1990s and it remains a core element of its successor, the Stop TB Strategy (Box 2). With the standard definitions of cases and treatment outcomes recommended by WHO and associated recording and reporting framework as a foundation, global monitoring of trends in case notifications and treatment outcomes has been possible since 1995.

In 2012, 6.1 million cases of TB were notified by NTPs and reported to WHO. 5.7 million were individuals newly diagnosed in 2012 and 0.4 million were previously diagnosed TB patients whose treatment regimen was changed. India and China accounted for 39% of notified cases of TB worldwide in 2012, African countries for 23% and the 22 HBCs for 82%. Notifications of TB cases have stabilized in recent years, and in 2012 represented 66% (64%–69%) of estimated incident cases (Fig. 2).

Most cases (88%) were aged 15–64 yr. Children (aged <15 yr) accounted for <10% of notified cases. The sex ratio (M/F) was 1.7, ranging from 1.0 to 2.1 among the six WHO regions. The reasons for higher TB notification rates in

![Graphs showing trends in estimated TB mortality rates excluding HIV during the period 1990–2012 and forecast TB mortality rates 2013–2015 by WHO region. Estimated TB mortality excludes TB deaths among HIV-positive people (which are classified as AIDS deaths). Shaded areas represent uncertainty bands. The horizontal dashed lines represent the Stop TB Partnership target of a 50% reduction in the mortality rate by 2015 compared with 1990. The other dashed lines show projections up to 2015.]
men are poorly understood (Ottmani and Up- 
lekar 2008). Possible explanations include bio-
logical differences between men and women in 
certain age groups that affect the risk of being 
infected as well as the risk of infection progres-
ing to active disease (Thorson et al. 2007), and 
differences in the societal roles of men and wom-
en that influence their risk of exposure to TB and 
access to care (gender differences) (Connolly 
and Nunn 1996; Borgdorff et al. 2000; Somma 
et al. 2008). The observation that TB notifica-
tion rates tend to be more equal between men 
and women in countries with a high prevalence 
of HIV supports the hypothesis of biological 
differences that can be lessened by immunolog-
ic suppression caused by HIV, but other non-
biological factors may play a role. Variation in 
the sex ratio among countries may reflect real 
differences in epidemiology as well as differen-
tial access to health care and use of services 
linked to the NTP. In some settings (e.g., Af-
ghanistan and the neighboring provinces 
of Iran and Pakistan), the sex ratio among noti-
fied cases is less than one. However, the recent 
national population-based survey in Pakistan 
(E Qadeer, R Fatima, S Tahseen, et al., unpubl.) 
confirmed findings from all other recent preva-
lence surveys to date that there are more men 
than women among prevalent TB cases (in Asian 
surveys conducted since 1990, the sex ratio has 
been between around 3 and 4), suggesting that 
women access TB care services linked to the NTP 
to a greater extent than men in some settings or 
that disease progression in those settings could 
be slower on average in women.

Globally, 87% of the new cases in 2011 were 
successfully treated (Fig. 4). The lowest treat-
ment success rates were in Africa (79%, despite 
steady improvement since 2006), in the region 
of the Americas (75%), and in the European 
region (72%); in the latter case probably because 
of a high prevalence of multidrug-resistant TB. 
Treatment success for MDR-TB patients is in 
general much lower (see below).

The provision of diagnosis and treatment 
according to the DOTS/Stop TB Strategy has 
resulted in major achievements in TB care and 
control. Between 1995 and 2012, 56 million 
people were successfully treated for TB in coun-
tries that had adopted the DOTS/Stop TB Strat-
ey, saving 22 million lives.

HIV-Associated TB

The 8.6 million incident TB cases in 2012 in-
cluded 1.0 million–1.2 million (12%–14%) 
among people living with HIV, with a best esti-
mate of 1.1 million (13%). The probability of

Figure 4. Treatment success rate, 2011 cohort of newly diagnosed TB cases (all forms). Countries shown in white 
did not report data to WHO for the 2011 cohort.
developing TB among people living with HIV divided by the probability of developing TB among HIV-negative people is the incidence rate ratio (IRR), a measure of the relative risk of TB in HIV-positive individuals compared with HIV-negative individuals. The estimated global IRR in 2012 was 29.6 (27.1–32.1).

The proportion of TB cases coinfected with HIV was highest in countries in the African region. Overall, 37% of TB cases were estimated to be coinfected with HIV in this region, which accounted for 75% of TB cases among people living with HIV worldwide. In parts of southern Africa, >50% of TB cases were coinfected with HIV. The number of people dying from HIV-associated TB has been decreasing since 2003. However, there were still 320,000 deaths from HIV-associated TB in 2012 and further efforts are needed to reduce this burden.

Globally, the percentage of notified TB patients with a documented HIV test result was 46% in 2012. In the African region, 74% of notified TB patients had an HIV test result in 2012. Among the 41 countries with the highest TB/HIV burden, 15 achieved HIV testing levels of ≥85%. There was an encouraging increase in ART coverage among HIV-positive TB patients between 2011 and 2012, from 49% worldwide in 2011 to 57% in 2012. Nonetheless, given the WHO recommendation that all HIV-positive TB patients are eligible for ART, the coverage of ART for HIV-positive TB patients still needs to be greatly improved. Antiretroviral therapy (ART) is expected to play an increasing role in preventing TB deaths as coverage expands (≏57% of notified TB cases estimated to be infected with HIV globally were on ART in 2012, compared with 16% in 2010) (Straetemans et al. 2010; Williams et al. 2010; Glaziou et al. 2011; WHO 2013a). ART and INH prophylaxis will also increasingly contribute to prevention of TB in individuals with both HIV infection and latent TB infection.

**Multidrug-Resistant TB**

Drug resistance, which develops as a result of inadequate treatment creating a selection pressure on spontaneously occurring mutants, complicates the management of TB; MDR- and XDR-TB represent one of the most important challenges in the control of TB worldwide (Raviglione and Uplekar 2006; Migliori et al. 2007a; Velayati et al. 2009; WHO 2011b; Udwadia et al. 2012).

Globally among notified TB cases, an estimated 3.6% of new cases and 20.2% of those previously treated have MDR-TB. Eastern Europe and central Asia have the highest MDR-TB percentage globally (up to 35% among new cases in some oblasts of Russia and Belarus), whereas important data gaps exist in the African region (Fig. 5). There were an estimated 450,000 (300,000–600,000) new cases of MDR-TB in 2012. These emerged either among incident TB cases (primary MDR-TB) or prevalent TB cases currently on treatment (acquired MDR-TB) in 2012. Among new and retreated TB patients known to National TB Programs that could have tested for drug resistance, there were an estimated 300,000 (220,000–380,000) MDR-TB cases in 2012; more than half of these cases were in India, China, and the Russian Federation. Of these 300,000 estimated cases, 94,000 were detected as having MDR-TB and 82% of those started on second-line treatment. However, treatment success globally remains well behind the conventional target of 75% set in the Global Plan to Stop TB (WHO 2011a), at only 48% in the 2010 patient cohort (the latest cohort for which data were available at in 2013, given treatment duration of around 2 years). Finally, deaths from MDR-TB in 2012 were estimated at 170,000 (100,000–240,000). Extensively drug-resistant TB (XDR-TB) has been so far reported from 92 countries worldwide. It is estimated that ~10% of the MDR-TB cases are XDR-TB.

By the end of June 2013, new diagnostics based on molecular techniques had started to be deployed in 88 low- and middle-income countries (WHO 2013a) and 49% of low and middle-income countries had incorporated WHO policy guidance on new diagnostics (Weyer et al. 2013) in their national guidelines. New diagnostics will make it possible for more people with drug-resistant disease to be detected earlier on in the course of their disease, thus improving outcomes.
Childhood TB

In 2012, an estimated 530,000 (510,000–550,000) children (aged 15 or less) fell ill with TB representing ≏6% of the global burden and there were 74,000 (59,000–90,000) deaths among HIV-negative children (representing ≏8% of total TB mortality among HIV-negative people). Out of the ≏350,000 TB notifications among children, 70% had pulmonary TB; most of these cases (≏80%) were diagnosed without bacteriological confirmation.

The traditionally low prioritization given to mostly noninfectious TB cases among children in overburdened health systems is aggravated by and has contributed to inadequate availability of diagnostic and treatment tools tailored to the needs of children, as well as to limitations in the availability of robust and nationally representative surveillance data. Nonetheless, growing attention to childhood TB in recent years has resulted in the development of clearly articulated actions for all stakeholders to address historical shortcomings. These include (1) strengthening surveillance through better recording and reporting and engagement with the private sector, especially pediatricians; (2) integrating TB screening in existing maternal and child health services, especially in TB endemic settings; and (3) addressing knowledge and research gaps in epidemiology, basic and operational research; and the development of new tools, such as diagnostics, drugs, vaccines (WHO 2013b).

TB PREVENTION AND CONTROL AFTER 2015

Incidence rates comparable with those currently found in low- and middle-income countries with a high burden of TB were recorded in North America and Western Europe as late as the early 20th century. A few of these countries have reliably documented their substantial reductions in case rates for more than 100 years (Styblo et al. 1969). The fastest nationwide declines of ≏10% per year occurred in the post-1945 period immediately after the second World War, when continued improvements in living conditions were combined with rapid economic growth, the introduction of effective chemotherapy, and universal (and largely free or not impoverishing) access to health care. Steeper reductions of 16% per year were recorded in two subpopulations with incidence rates 10 times higher than the 2012 global average (Canadian Inuits
[Enarson and Grzybowski 1986] and Alaskan Eskimos [Grzybowski et al. 1976]) in the 1950s and 1960s, thanks to effective treatment programs combined with mass screening and preventive therapy. The current best performers among high-burden countries, such as Cambodia, China, and Rwanda, have recently achieved reductions of $\sim 3\%–5\%$ per year and the global decline in incidence is only $2\%$ per year. With current tools, effective TB control should be able to achieve faster reductions in incidence of $5\%–10\%$ per year (Dye et al. 2013). The 2050 target of TB elimination is most likely to be achieved if, besides early detection and treatment of active TB cases, latent infection is treated and active disease prevented with either such an easily administered preventive treatment or a new vaccine (Dye and Williams 2008). This will require new and better tools.

To date, only BCG vaccination, provided to $\sim 80\%$ of the annual birth cohort, and treatment of active TB using first-line drugs, have been implemented on a large scale (Lonnroth et al. 2010; Raviglione et al. 2012a). With these interventions that result in a global decline of some $2\%$ per year, elimination (less than one case per million population) will not be achieved by 2050 (Lonnroth and Raviglione 2008). A rapid reduction in TB incidence and mortality in excess of what has been achieved historically requires more effective implementation of existing tools and the development and widespread use of a highly effective and safe new vaccine or prophylactic treatment (PT) to prevent reactivation of TB disease among the estimated 2 billion infected people (Dye et al. 1999; WHO 2012b) already. Currently, the only vaccine for TB prevention (BCG) dates from the 1920s and is mainly effective in preventing severe forms of TB in children, whereas its efficacy in the infectious adult forms of TB varies according to settings and populations not resulting in any large-scale protection. The earliest date at which a new vaccine may become available is now estimated as early to mid 2020. Randomized controlled trials of PT have shown that up to 9 mo of daily INH for treatment of latent infection confers $25\%–92\%$ protection against developing active TB, with results toward the upper end of this range when patients adhere fully to the treatment regimen (Sterling 2008). Isoniazid, alone or in combination (Sterling et al. 2011), is also a relatively safe drug. Its main side effect, hepatitis, occurs in $1\%$ of patients; however, four to seven treated individuals per 100,000 may develop fatal hepatitis (Millard et al. 1996). The high risk of TB among people coinfected with $M. tuberculosis$ and HIV is a reason for promoting much greater use in settings with a high prevalence of HIV (Woldehanna and Volmink 2004; Churchyard et al. 2007). To date, however, PTs with INH or combinations of drugs are not widely used.

First-line treatments that cure $\sim 90\%$ of drug-susceptible cases remain long (6 mo) and are based on drug combinations dating from the 1970s. In mid-2013, there were 12 vaccine candidates for TB prevention in clinical trials and 10 new or repurposed drugs in late phases of clinical development. Two new drugs belonging to two novel classes of antibiotics were approved by strict regulatory authorities in the past 15 mo—the dyaarilquinoline, bedaquiline (Diacon et al. 2012) and the nitroimidazole, delamanid (Gler et al. 2012). These two drugs offer hope of better outcomes in severe cases of MDR-TB, but have not yet been tested to shorten treatment of drug-susceptible TB or as preventive treatment. Various new diagnostic tests and methods have been endorsed since 2007, although a point-of-care test remains elusive. Research and development related to new drugs, new diagnostics, and new vaccines has accelerated in recent years (Lonnroth and Raviglione 2008; Ly and McMurray 2008; Pai and O’Brien 2008; Lienhardt et al. 2012a,b; Nicolau et al. 2012; Raviglione et al. 2012a; WHO 2013a).

Besides PT, there is considerable scope to expand interventions to reduce TB-related mortality in HIV-positive people. ART decreases the incidence of TB among people living with HIV (although more research is needed to understand the impact of large scale ART programs on TB epidemics) and reduces mortality. Cotrimoxazole preventive therapy (CPT) for HIV-positive TB patients reduces mortality (Grimwade et al. 2005; Harries et al. 2009). Recent expansion of TB control in areas in which the
prevalence of HIV is high has also exposed a neglect of the basic principles of infection control, in which immunosuppressed patients have been exposed to patients with active TB in clinics and hospitals (Bock et al. 2007; Wells et al. 2007).

Provision of diagnosis and treatment for cases of MDR-TB is mostly confined to the European region, North America, and South Africa (WHO 2013a). Urgent improvements in the provision of services for laboratory culture and DST, new rapid drug susceptibility tests as well as treatment are needed in many countries. The emergence of XDR-TB (Migliori et al. 2007b; Shah et al. 2007) has reinforced the need for updated plans to improve the performance of TB control, including prevention of additional acquisition of resistance, transmission of resistant strains, and the capacity to diagnose and provide adequate treatment for drug-resistant TB (Manissero and Fernandez de la Hoz 2006; Raviglione 2006a; Raviglione and Smith 2007).

In addition to scaling up interventions related to treatment of latent infection, TB/HIV, and MDR-TB, the Stop TB Strategy emphasizes the importance of engaging the full range of health-care providers. These include those in prisons and the armed forces, private clinicians, services provided by nongovernmental organizations, faith-based organizations, and mission services and hospitals, and clinics in the corporate sector (Lonnroth et al. 2004; Ambe et al. 2005; Lonnroth and Uplekar 2005; Floyd et al. 2006; Pantoja et al. 2009). Such engagement can shorten delays to diagnosis and ensure that treatment for all patients (in both the public and the nonstate sector) meets international standards (Hopewell et al. 2006).

As in the immediate post–World War II period, a paradigm shift in the tools available for TB control is now needed, in the context of Universal Health Coverage (WHO 2012a). Incidence would need to decline as fast as 20% per year on average for the elimination target to be achieved by 2050. Wider application of existing interventions combined with development and implementation of new tools is required, as set out in the Stop TB Strategy and the Global Plan to Stop TB (Raviglione 2006b, 2007). In addition, TB control and prevention need to be placed in the wider context of health and development (Dye and Raviglione 2013). The challenge will be to incorporate new tools into TB control practices while also strengthening overall health systems and ensuring wider access to prevention, diagnostic, and treatment. In 2012, WHO initiated work on a new post-2015 global TB strategy that incorporates all of these elements; it is anticipated that the strategy and associated operational guidance will be finalized by 2015.

Recognition that TB depends largely on social and economic determinants of ill health is crucial to achieve full control and elimination. Factors such as smoking, alcohol abuse, diabetes, indoor air pollution, and malnutrition that, like HIV, are impacting on TB epidemiology impeding faster progress toward its control (Lonnroth et al. 2009; Lienhardt et al. 2012a). Preventive strategies may result in remarkable outcomes among certain vulnerable groups, such as people with diabetes and those infected with HIV. Reductions in levels of smoking, alcohol abuse, malnutrition, and indoor air pollution will likely be associated with reduction in TB infection and disease. Ultimately, education, health promotion, universal health coverage (Moreno-Serra and Smith 2012), and poverty-reduction strategies will have an effect on the TB epidemic by removing progressively individuals from the vulnerable pool.

CONCLUSIONS

Major gains were achieved in TB control over the past two decades. Between 1995 and 2012, 22 million lives were saved in countries that had adopted the DOTS/Stop TB Strategy (WHO 2013a) and international TB targets for 2015 will likely be met at the global level (WHO 2013a). Nonetheless, the burden of TB remains high and affects disproportionately poor and disadvantaged populations worldwide (Squire et al. 2006), and whereas the burden of TB is declining, the rate of progress is too slow. The accelerated development of new tools allows for a more optimistic view of the future course
of the TB pandemic. A post-2015 global strategy to control TB will necessarily include the successful development and application of new and safe prophylactic treatments and effective vaccines (Raviglione et al. 2012b) administered on a very large scale. While pursuing new tool research and development, global adoption and rapid implementation of the universal healthcare agenda and effectively addressing determinants of TB will be the key to accelerating the decline in incidence.

ACKNOWLEDGMENTS

We sincerely thank Matteo Zignol and Dennis Falzon for their contribution to the section on drug-resistant tuberculosis. The World Health Organization (WHO) has graciously granted the authors and publishers permission to publish this material, which remains exclusively vested in WHO.

REFERENCES


Cite this article as Cold Spring Harb Perspect Med 2015;5:a017798

Global Epidemiology of TB
P. Glaziou et al.


Global Epidemiology of TB
Global Epidemiology of Tuberculosis

Philippe Glaziou, Charalambos Sismanidis, Katherine Floyd and Mario Raviglione

Cold Spring Harb Perspect Med 2015; doi: 10.1101/cshperspect.a017798 originally published online October 30, 2014

Subject Collection  Tuberculosis

Transmission and Institutional Infection Control of Tuberculosis
Edward A. Nardell

Innate and Adaptive Cellular Immune Responses to Mycobacterium tuberculosis Infection
Katrin D. Mayer-Barber and Daniel L. Barber

Tuberculosis Comorbidity with Communicable and Noncommunicable Diseases
Matthew Bates, Ben J. Marais and Alimuddin Zumla

Host-Directed Therapies for Tuberculosis
David M. Tobin

Immunity and Immunopathology in the Tuberculous Granuloma
Antonio J. Pagán and Lalita Ramakrishnan

Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm?
Sumit Chakraborty and Kyu Y. Rhee

Genetic Approaches to Facilitate Antibacterial Drug Development
Dirk Schnappinger

The Tuberculosis Drug Discovery and Development Pipeline and Emerging Drug Targets
Khismuzi Mduli, Takushi Kaneko and Anna Upton

Clinical Aspects of Adult Tuberculosis
Robert Loddenkemper, Marc Lipman and Alimuddin Zumla

Advances in Diagnostic Assays for Tuberculosis
Stephen D. Lawn

Diagnosis and Management of Latent Tuberculosis Infection
Laura Muñoz, Helen R. Stagg and Ibrahim Abubakar

Mycobacterial Growth
Iria Uhía, Kerstin J. Williams, Vahid Shahrezaei, et al.

Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis
Kwonjune J. Seung, Salmaan Keshavjee and Michael L. Rich

The Mycobacterial Cell Wall—Peptidoglycan and Arabinogalactan

Tuberculosis and HIV Coinfection
Judith Bruchfeld, Margarida Correia-Neves and Gunilla Källenius

Imaging in Tuberculosis

For additional articles in this collection, see http://perspectivesinmedicine.cshlp.org/cgi/collection/

Copyright © 2015 Cold Spring Harbor Laboratory Press; all rights reserved